Microsatellite Alterations of Plasma DNA in Non-Small Cell Lung Cancer

被引:0
作者
Kim, Kyu-Sik [1 ,2 ]
Kim, Eun-Jung [2 ]
Kim, Soo-Ock [2 ]
Oh, In-Jae [2 ]
Park, Chang-Min [2 ]
Jeong, Ju-Yeon [1 ,2 ]
Kim, Yu-Il [2 ]
Lim, Sung-Chul [2 ]
Park, Jong-Tae [3 ]
Kim, Young-Chul [1 ,2 ]
机构
[1] Chonnam Natl Univ, Hwasun Hosp, Lung & Esophageal Canc Clin, Hwasun, South Korea
[2] Chonnam Natl Univ, Sch Med, Dept Pulmonol & Crit Care Med, Hwasun, South Korea
[3] Chonnam Natl Univ, Sch Med, Dept Forens Med, Hwasun, South Korea
关键词
Non-Small Cell Lung cancer; Microsatellite Alteration; Plasma DNA;
D O I
10.4046/trd.2005.58.4.352
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Microsatellites are short tandem repeated nucleotide sequences that are present throughout the human genome. Variations in the repeat number or a loss of heterozygosity around the microsatellites have been termed a microsatellite alteration (MA). A MA reflects the genetic instability caused by an impairment in the DNA mismatch repair system and is suggested to be a novel tumorigenic mechanism. A number of studies have reported that MA in the DNA extracted from the plasma occurs at varying frequencies among patients with a non-small cell lung carcinoma (NSCLC). The genomic DNA from 9 subjects with a non-small cell lung cancer (squamous cell cancer 6, adenocarcinoma 2, non-small cell lung cancer1) and 9 age matched non-cancer control subjects (AMC: tuberculosis 3, other inflammatory lung disease 6) and 12 normal control subjects (NC) were extracted from the peripheral blood leukocytes and plasma. Three microsatellite loci were amplified with the primers targeting the Gene Bank sequence D21S1245, D3S1300, and D3S1234. MA in the form of an allelic loss or a band shift was examined with 6% polyacrylamide gel electrophoresis and silver staining. None (0/12) of the NC subjects less than 40 years of age showed a MA in any of the three markers, while 88.9%(8/9) of the AMC above 40 showed a MA in at least one of the three markers (p< 0.05). Sixty percent(6/10) of the control subjects with a smoking history showed a MA in one of the three markers, while 9.1%(1/11) of the control subjects without smoking history showed a MA (p< 0.05). However, not only did 66.7%(6/9) of lung cancer patients show a MA in at least one of the three markers but so did 88.9%(8/21) of the AMC patients (p> 0.05). In conclusion, a MA in the D21S1245, D3S1300, and D3S1234 loci using DNA extracted from the plasma was detected in 66.7% of lung cancer while no MA was found in the young non-smoking control subjects. However, many of the non-cancer control subjects (aged smokers) also showed a MA, which compromised the specificity of the MA analysis as a screening test. Therefore, a further study with a larger sample size will be needed.
引用
收藏
页码:352 / 358
页数:7
相关论文
共 50 条
  • [21] Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer
    M. Saigi
    A. McLeer-Florin
    E. Pros
    E. Nadal
    E. Brambilla
    M. Sanchez-Cespedes
    Clinical and Translational Oncology, 2018, 20 : 881 - 888
  • [22] Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer
    Cai, Liangliang
    Bai, Hua
    Duan, Jianchun
    Wang, Zhijie
    Gao, Shugeng
    Wang, Di
    Wang, Shuhang
    Jiang, Jun
    Han, Jiefei
    Tian, Yanhua
    Zhang, Xue
    Ye, Hao
    Li, Minghui
    Huang, Bingding
    He, Jie
    Wang, Jie
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [23] Circulating DNA is a Useful Prognostic Factor in Patients with Advanced Non-small Cell Lung Cancer
    Sirera, Rafael
    Bremnes, Roy M.
    Cabrera, Andrea
    Jantus-Lewintre, Eloisa
    Sanmartin, Elena
    Blasco, Ana
    del Pozo, Nieves
    Rosell, Rafael
    Guijarro, Ricardo
    Galbis, Jose
    Javier Sanchez, Jose
    Camps, Carlos
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (02) : 286 - 290
  • [24] DNA damage repair gene alterations influence the tumor immune microenvironment in advanced non-small cell lung cancer
    Sankar, Kamya
    Mercer, Jacob
    Jaeger, Ellen B.
    Godden, Jen
    Williams, Edward
    Thompson, Michael A.
    Patel, Shetal A.
    Figueiredo, Jane C.
    Weinberg, Frank
    Reckamp, Karen L.
    LUNG CANCER, 2025, 201
  • [25] Molecular evidence of viral DNA in non-small cell lung cancer and non-neoplastic lung
    Robinson, Lary A. l
    Jaing, Crystal J.
    Campbell, Christine Pierce
    Magliocco, Anthony
    Xiong, Yin
    Magliocco, Genevra
    Thissen, James B.
    Antonia, Scott
    BRITISH JOURNAL OF CANCER, 2016, 115 (04) : 497 - 504
  • [26] Gefitinib in non-small cell lung cancer
    Tamura, K
    Fukuoka, M
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) : 985 - 993
  • [27] Oligoprogression in Non-Small Cell Lung Cancer
    Harada, Daijiro
    Takigawa, Nagio
    CANCERS, 2021, 13 (22)
  • [28] Angiogenesis and non-small cell lung cancer
    Cox, G
    Jones, JL
    Walker, RA
    Steward, WP
    O'Byrne, KJ
    LUNG CANCER, 2000, 27 (02) : 81 - 100
  • [29] Immunotherapy for non-small cell lung cancer
    Vafadar, Sam
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2019, 32 (09): : 37 - 42
  • [30] Ifosfamide in non-small cell lung cancer
    Boni, C
    Zanelli, F
    ONCOLOGY, 2003, 65 : 50 - 54